| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Influenza A virus hemagglutinin HA. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Influenzavirus A (IAV) |
| Isotype | IgG1, κ |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; DB; ELISA; IHC; FC; IP; IF; FuncS |
| Application Notes | The antibody is recommended for detection of IAV HA by ELISA, IHC, FC, IP, IF, FuncS assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | IAV HA |
| Alternative Name | Influenza A virus hemagglutinin HA |
| Research Area | Infectious Disease |
| Related Disease | Influenza A infection |
Figure 1 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in SDS-PAGE
SDS-PAGE analysis of V3S-0522-YC1438 in non-reduced (Lane 1, 1.5 μg) and β-mercaptoethanol-reduced (Lane 2, 1.5 μg) and non-reduced (Lane 2, 1.5 μg) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result, different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 1 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in SDS-PAGE
Figure 2 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in SEC-HPLC
The purity of V3S-0522-YC1438 was 97.661% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl
Figure 2 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in SEC-HPLC
Figure 3 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
ELISA analysis of V3S-0522-YC1438 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC1438. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
Figure 4 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
ELISA analysis of V3S-0522-YC1438 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC1438. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
Figure 5 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
ELISA analysis of V3S-0522-YC1438 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC1438. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 5 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
Figure 6 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
ELISA analysis of V3S-0522-YC1438 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC1438. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 6 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in ELISA
Figure 7 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in WB
Western blot analysis of V3S-0522-YC1438 was performed by loading Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC1438 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.8 μg)
Figure 7 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in WB
Figure 8 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in WB
Western blot analysis of V3S-0522-YC1438 was performed by loading Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC1438 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.8 μg)
Figure 8 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in WB
Figure 9 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in WB
Western blot analysis of V3S-0522-YC1438 was performed by loading Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC1438 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.8 μg)
Figure 9 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in WB
Figure 10 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Dot Blot analysis of V3S-0522-YC1438 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC1438 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 10 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Figure 11 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Dot Blot analysis of V3S-0522-YC1438 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC1438 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 11 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Figure 12 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Dot Blot analysis of V3S-0522-YC1438 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC1438 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 12 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Figure 13 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
Dot Blot analysis of V3S-0522-YC1438 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His tag).
V3S-0522-YC1438 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 13 Anti-IAV HA Monoclonal Antibody (V3S-0522-YC1438) in DB
